Antibiotic Prophylaxis in Rhinoplasty

This study compares the efficacy of a single intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides), alone versus both intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides) and postoperative oral dose of "cephalexin" or "clindamycin" use in nasal surgery.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Washington University School of Medicine

Stanford Investigator(s):

Intervention(s):

  • Drug: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg.
  • Drug: Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days

Phase:

Phase 3

Eligibility


Inclusion Criteria:

Adult patients (aged 18years and older)

Exclusion Criteria:

   - Prior rhinoplasty

   - Any exogenous (non-nasal) grafts/implants

   - Immune deficiency (DM, meds, other)

   - History of radiotherapy to nose

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Sam P Most, MD
6507363223
Not Recruiting